Scarica l'app Stockscreener
314.56
3.21%
-10.43
Pre-mercato:
322.42
7.86
+2.50%
Precedente Chiudi:
$324.99
Aprire:
$320
Volume 24 ore:
237.40K
Relative Volume:
0.49
Capitalizzazione di mercato:
$8.77B
Reddito:
$7.46M
Utile/perdita netta:
$-326.53M
Rapporto P/E:
-23.51
EPS:
-13.3803
Flusso di cassa netto:
$-282.53M
1 W Prestazione:
+0.34%
1M Prestazione:
+18.00%
6M Prestazione:
+12.01%
1 anno Prestazione:
+522.40%
Intervallo 1D:
$308.24
$327.26
Intervallo di 1 settimana:
$307.00
$343.11
Portata 52W:
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
314.56 | 8.77B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Strong Buy |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-02 | Iniziato | Wells Fargo | Equal Weight |
| 2025-12-15 | Reiterato | Oppenheimer | Outperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
PRAX Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
Piper Sandler reiterates Praxis Precision Medicines stock rating - Investing.com
Goldman Sachs initiates Praxis Precision Medicines stock coverage with buy rating - Investing.com
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Understanding the Setup: (PRAX) and Scalable Risk - Stock Traders Daily
Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says - Moomoo
Praxis Precision Medicines explores neurology pipeline as Nasdaq-listed biotech refines its focus - Ad Hoc News
Form 4 Praxis Precision Medicines Inc For: 8 July By Investing.com - Investing.com Nigeria
Praxis Precision Medicines Inc. (PRAX) Q1 2026 Earnings: Surprise Beat on EPS as Clinical Pipeline AdvancesRevenue Miss Report - dars.gov.et
Praxis (PRAX) CEO Marcio Souza gifts 23,121 shares, retains 56,495 - Stock Titan
Praxis Precision (PRAX) Partners with Remagine Labs for Innovati - GuruFocus
Praxis Precision Medicines Partners with Remagine Labs to Develop Innovative Transdermal Patch for Ulixacaltamide Delivery in Essential Tremor – Minichart - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Praxis (PRAX) teams with Remagine Labs on transdermal ulixacaltamide for essential tremor - Stock Titan
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - Investing News Network
Praxis bets on skin patch for essential tremor drug - Stock Titan
S&P 500 Futures Climb In Premarket Trading; Praxis Precision Meds, IREN Lead - Moomoo
If You Invested $1,000 in Praxis Precision Medicines, Inc. (PRAX) - Stock Titan
PRAX stock. Praxis Precision Medicines holds the spotlight on thin news - Ad-hoc-news.de
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor - Stock Titan
Praxis uses inducement plan to grant 951 shares to five hires - Stock Titan
Price to sales forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Enterprise value to revenue forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Jefferies Keeps Their Buy Rating on Praxis Precision Medicines (PRAX) - The Globe and Mail
Price to book forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
We Think Praxis Precision Medicines (NASDAQ:PRAX) Can Easily Afford To Drive Business Growth - Moomoo
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $719 - Moomoo
The Technical Signals Behind (PRAX) That Institutions Follow - Stock Traders Daily
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $510 to $1,200 - Moomoo
Enterprise value to EBIT forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis sees encephalopathies asset relutrigine action date extended - MSN
PRAX Maintained by Needham -- Price Target Raised to $575 - GuruFocus
Price to earnings forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines (PRAX) Surges Nearly 7% as Momentum BuildsVolatility Stop - dars.gov.et
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Praxis Precision Medicines stock falls on FDA review delay By Investing.com - Investing.com South Africa
FDA Extends Review Timeline for Praxis’ Relutrigine NDA - TipRanks
Praxis Precision Medicines stock falls on FDA review delay - Investing.com UK
FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026 - Stock Titan
Praxis Precision Medicines Announces FDA Extends Review of Relutrigine NDA to December 27, 2026 - Quiver Quantitative
Praxis Precision Medicines Announces Extension Period for - GlobeNewswire
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell 3000E Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
FDA delays Praxis relutrigine review by three months to Dec. 27 - Stock Titan
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell Microcap Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Praxis Precision Medicines Inc Azioni (PRAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DeSimone Jill | Director |
Jun 24 '26 |
Sale |
311.32 |
11,600 |
3,611,335 |
2,337 |
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):